Targeting PI3K signalling in cancer: pros and cons

Cited in blog · Nature Reviews Cancer, 9(8), 550-562. · 2009

Engelman JA (2009). Targeting PI3K signalling in cancer: pros and cons. Nature Reviews Cancer, 9(8), 550-562.

Authors

Engelman JA

Research lens

Engelman JA (2009). Targeting PI3K signalling in cancer: pros and cons. Nature Reviews Cancer, 9(8), 550-562.

  • blog
  • novartis-pacibekitug-inflammation-2026-09-03